ICE Bioscience

ICE Bioscience

生物技术研究

We aim to break through barriers in drug discovery and contribute our efforts to the global healthcare cause.

关于我们

ICE Bioscience was founded in 2010 as an Innovative CRO+ Explorer company. We specialize in early drug discovery services, spanning from target validation to the identification of pre-clinical candidates. Currently, ICE Bioscience offers a broad selection of off-the-shelf assays, including 100+ ion channels, 800+ Kinases/enzymes, 100+ GPCRs, and 40+ nuclear receptor assays, all accompanied by validation data and screening information. This comprehensive range of assays provides us with a competitive edge, as it covers a vast majority of druggable targets. Our company has established multiple platforms, encompassing Protein Engineering, Cell Line Development, Target Based Assays, Safety Pharmacology, Translational Biology, DMPK, In Vivo Pharmacology and Biophysical Assays, enabling us to smoothly execute the DMTA cycle (Design-Make-Test-Analysis cycle) for innovative drug discovery in collaboration with our clients.

所属行业
生物技术研究
规模
201-500 人
总部
Beijing
类型
合营企业
创立
2010
领域
In vitro pharmacology、DMPK、Target based assays、Kinase profiling、Safety pharmacology、GPCR、electrophysiology、Drug Discovery、Transporter、ADME、Custom assay development、Ion Channel、MOA studies、Cell based assays、Biochemical assays、Biophysical assays和Enzymology

地点

  • 主要

    Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China

    CN,Beijing

    获取路线

ICE Bioscience员工

动态

相似主页